skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure

Review

(1851) Views  (538) Full article downloads

Authors: Donatella Del Sindaco, Maria Denitza Tinti, Luca Monzo, et al

Published Date December 2010 Volume 2010:5 Pages 381 - 393
DOI: http://dx.doi.org/10.2147/CIA.S4482

Donatella Del Sindaco1, Maria Denitza Tinti2, Luca Monzo2, Giovanni Pulignano2,
1Heart Failure Unit, Division of Cardiology, INRCA Institute of Care and Research for Elderly, Rome, Italy; 2Heart Failure Clinic, Division of Cardiology/CCU, San Camillo Hospital, Rome, Italy

Abstract: Heart failure is a common and disabling condition with morbidity and mortality that increase dramatically with advancing age. Large observational studies, retrospective subgroup analyses and meta-analyses of clinical trials in systolic heart failure, and recently published randomized studies have provided data supporting the use of beta-blockers as a baseline therapy in heart failure in the elderly. Despite the available evidence about beta-blockers, this therapy is still less frequently used in elderly compared to younger patients. Nebivolol is a third-generation cardioselective beta-blocker with L-arginine/nitric oxide-induced vasodilatory properties, approved in Europe and several other countries for the treatment of essential hypertension, and in Europe for the treatment of stable, mild, or moderate chronic heart failure, in addition to standard therapies in elderly patients aged 70 years old or older. The effects of nebivolol on left ventricular function in elderly patients with chronic heart failure (ENECA) and the study of effects of nebivolol intervention on outcomes and rehospitalization in seniors with heart failure (SENIORS) have been specifically aimed to assess the efficacy of beta-blockade in elderly heart failure patients. The results of these two trials demonstrate that nebivolol is well tolerated and effective in reducing mortality and morbidity in older patients, and that the beneficial clinical effect is present also in patients with mildly reduced ejection fraction. Moreover, nebivolol appears to be significantly cost-effective when prescribed in these patients. However, further targeted studies are needed to better define the efficacy as well as safety profile in frail and older patients with comorbid diseases.

Keywords: beta-blockers, therapy, older, left ventricular dysfunction, prognosis






Readers of this article also read:

Arterial stiffness, hypertension, and rational use of nebivolol
Poor tolerance of beta-blockers by elderly patients with heart failure
Clinical intervention in aging: ethicolegal issues in assessing risk and benefit
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
Critical appraisal of cabazitaxel in the management of advanced prostate cancer
Treatment of post-partum depression: a review of clinical, psychological and pharmacological options
Clinical update on the use of biomarkers of airway inflammation in the management of asthma
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Thyroid dysfunction in pregnancy
Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids